Johnson & Johnson (JNJ)

126.92
0.61 0.48
NYSE : Health Care
Prev Close 127.53
Open 127.25
Day Low/High 126.83 / 127.67
52 Wk Low/High 109.32 / 129.00
Volume 4.01M
Avg Volume 6.09M
Exchange NYSE
Shares Outstanding 2.69B
Market Cap 343.54B
EPS 6.00
P/E Ratio 21.43
Div & Yield 3.36 (2.60%)

Latest News

Johnson & Johnson Becomes #15 Most Shorted Dow Stock, Replacing General Electric

The most recent short interest data has been released for the 05/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Johnson & Johnson Settles U.S. Drug Manufacturing Probe

Johnson & Johnson Settles U.S. Drug Manufacturing Probe

The $33 million settlement was announced by the attorney general on behalf of 42 states and the District of Columbia.

Nasdaq Gets Way Out of Line

As points climb, shouldn't breadth improve just as much?

Post Script; Takeaways and Observations: Doug Kass' Views

Post Script; Takeaways and Observations: Doug Kass' Views

Doug Kass shares his thoughts on Treasury notes and bonds, and offers some other observations.

Johnson & Johnson Unit Sues to Block Sale of Copy of its Rheumatoid Arthritis Drug

Johnson & Johnson Unit Sues to Block Sale of Copy of its Rheumatoid Arthritis Drug

South Korea's Samsung Bioepis is looking to sell its version of the drug in the U.S.

The Dollar Breakdown Has Legs

The Dollar Breakdown Has Legs

A bearish momentum indicator is about to be formed.

Sweet Play Going Ex-Dividend Next Week

Hershey is among more than 100 stocks and funds going ex-dividend in the week ahead.

Johnson & Johnson Execs Discuss Drug Pipeline

Johnson & Johnson Execs Discuss Drug Pipeline

Company officials conducted a pharmaceutical business review meeting with industry analysts on Wednesday.

Johnson & Johnson Showcases Strong Pipeline Of Transformational Medicines At Its Pharmaceutical Business Review Meeting

- Company expects more than 10 new blockbuster products to launch or file for regulatory approval by 2021

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.

Don't Let Go of the Tight Stops

Don't Let Go of the Tight Stops

When it comes to the VIX, don't be a member of the consensus.

Watch Johnson & Johnson Break Record Highs

Watch Johnson & Johnson Break Record Highs

Shares of JNJ have been moving well since the opening bell and are now well above the April peak.

3 Health Care Stocks to Own for 2017

3 Health Care Stocks to Own for 2017

Medtronic, J&J and Cardinal Health appear poised to benefit from an aging U.S. population, say investment experts.

Johnson & Johnson Stock Rises on JPMorgan Upgrade

Johnson & Johnson Stock Rises on JPMorgan Upgrade

JPMorgan analyst Michael Weinstein contended that the negative sentiment encompassing the stock might be overdone.

Analysts' Actions -- Cisco, J.C. Penney, Johnson & Johnson, Tesla and More

Analysts' Actions -- Cisco, J.C. Penney, Johnson & Johnson, Tesla and More

Here are Monday's top research calls, including upgrades for Cisco Systems and Johnson & Johnson, and downgrades for J.C. Penney and Tesla.

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

Google's YouTube to Offer New Shows With Ellen DeGeneres, Kevin Hart to Attract Premium Ad Dollars

Google's YouTube to Offer New Shows With Ellen DeGeneres, Kevin Hart to Attract Premium Ad Dollars

YouTube is making a push into original content after suffering from a boycott from top advertisers in March.

Jury Finds Against Johnson & Johnson in Baby Powder Lawsuit

Jury Finds Against Johnson & Johnson in Baby Powder Lawsuit

Johnson & Johnson is standing behind its product.

Hit by Generic Deflation, Cardinal Health Expects Pricing to Stabilize Through 2017

Hit by Generic Deflation, Cardinal Health Expects Pricing to Stabilize Through 2017

The Cordis and Medtronic acquisitions are meant to shield Cardinal from the pricing swings of drug distribution.

Earnings Trades: How and Why They Can Succeed

Here's the reason we can justify trades like GOOGL and SBUX last week.

Why Investors Should Factor in Goodwill When Evaluating Stocks

Why Investors Should Factor in Goodwill When Evaluating Stocks

Investors should consider factoring in goodwill when they are examining the value of a stock because it can often predict the outlook of a company, especially serial acquirers.

Morgan Stanley, Kirkland Two Busiest Dealmakers in First Quarter

Morgan Stanley, Kirkland Two Busiest Dealmakers in First Quarter

Morgan Stanley leads the banks, while Kirkland & Ellis tops the law firms.

Wait for This Correction in Johnson & Johnson to End

Wait for This Correction in Johnson & Johnson to End

Let's pull the band aid off the charts, carefully.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.